Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?

Stefanie Purdon, Carissa L. Patete, Marilyn K Glassberg Csete

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell therapy over the years spanning across many countries. The reality, however, is that the science behind this therapy is lagging. While there have been promising results from phase I trials, there remain multiple reasons that “stem cells” are not ready for clinical application, starting from a gap in understanding at the bench research level, all the way to optimal clinical application in order to provide effective therapy.

Original languageEnglish (US)
Pages (from-to)390-393
Number of pages4
JournalAmerican Journal of the Medical Sciences
Volume357
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Pulmonary Fibrosis
Mesenchymal Stromal Cells
Stem Cells
Idiopathic Pulmonary Fibrosis
Therapeutics
Complementary Therapies
Cell- and Tissue-Based Therapy
Growth
Research

Keywords

  • Idiopathic pulmonary fibrosis
  • Stem cells
  • Therapies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis? / Purdon, Stefanie; Patete, Carissa L.; Glassberg Csete, Marilyn K.

In: American Journal of the Medical Sciences, Vol. 357, No. 5, 01.05.2019, p. 390-393.

Research output: Contribution to journalReview article

@article{c6441a3e5eeb433bac276f2211560b36,
title = "Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?",
abstract = "With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell therapy over the years spanning across many countries. The reality, however, is that the science behind this therapy is lagging. While there have been promising results from phase I trials, there remain multiple reasons that “stem cells” are not ready for clinical application, starting from a gap in understanding at the bench research level, all the way to optimal clinical application in order to provide effective therapy.",
keywords = "Idiopathic pulmonary fibrosis, Stem cells, Therapies",
author = "Stefanie Purdon and Patete, {Carissa L.} and {Glassberg Csete}, {Marilyn K}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.amjms.2019.02.007",
language = "English (US)",
volume = "357",
pages = "390--393",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?

AU - Purdon, Stefanie

AU - Patete, Carissa L.

AU - Glassberg Csete, Marilyn K

PY - 2019/5/1

Y1 - 2019/5/1

N2 - With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell therapy over the years spanning across many countries. The reality, however, is that the science behind this therapy is lagging. While there have been promising results from phase I trials, there remain multiple reasons that “stem cells” are not ready for clinical application, starting from a gap in understanding at the bench research level, all the way to optimal clinical application in order to provide effective therapy.

AB - With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell therapy over the years spanning across many countries. The reality, however, is that the science behind this therapy is lagging. While there have been promising results from phase I trials, there remain multiple reasons that “stem cells” are not ready for clinical application, starting from a gap in understanding at the bench research level, all the way to optimal clinical application in order to provide effective therapy.

KW - Idiopathic pulmonary fibrosis

KW - Stem cells

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=85063873972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063873972&partnerID=8YFLogxK

U2 - 10.1016/j.amjms.2019.02.007

DO - 10.1016/j.amjms.2019.02.007

M3 - Review article

C2 - 31010466

AN - SCOPUS:85063873972

VL - 357

SP - 390

EP - 393

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 5

ER -